Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2023 | Aug. 02, 2023 | |
Cover [Abstract] | ||
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2023 | |
Document Transition Report | false | |
Entity Registrant Name | Quanterix Corp | |
Entity File Number | 001-38319 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 20-8957988 | |
Entity Address, Address Line One | 900 Middlesex Turnpike | |
Entity Address, City or Town | Billerica | |
Entity Address, State or Province | MA | |
Entity Address, Postal Zip Code | 01821 | |
City Area Code | 617 | |
Local Phone Number | 301-9400 | |
Title of 12(g) Security | Common Stock, $0.001 par value per share | |
Trading Symbol | QTRX | |
Security Exchange Name | NASDAQ | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 37,552,586 | |
Entity Central Index Key | 0001503274 | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Year Focus | 2023 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false |
CONSOLIDATED BALANCE SHEETS
CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Current assets: | ||
Cash and cash equivalents | $ 329,525 | $ 338,740 |
Accounts receivable (net of allowance for expected credit losses of $442 and $118 as of June 30, 2023 and December 31, 2022, respectively) | 24,423 | 19,017 |
Inventory | 18,156 | 16,786 |
Prepaid expenses and other current assets | 6,954 | 6,860 |
Total current assets | 379,058 | 381,403 |
Restricted cash | 2,686 | 2,597 |
Property and equipment, net | 18,328 | 20,162 |
Intangible assets, net | 6,476 | 7,516 |
Operating lease right-of-use assets | 20,380 | 21,223 |
Other non-current assets | 2,282 | 1,298 |
Total assets | 429,210 | 434,199 |
Current liabilities: | ||
Accounts payable | 3,238 | 3,836 |
Accrued compensation and benefits | 7,525 | 10,658 |
Accrued expenses and other current liabilities | 6,777 | 5,133 |
Deferred revenue | 10,421 | 8,644 |
Operating lease liabilities | 3,986 | 2,687 |
Total current liabilities | 31,947 | 30,958 |
Deferred revenue, net of current portion | 1,304 | 1,415 |
Lease liabilities, net of current portion | 39,378 | 41,417 |
Other non-current liabilities | 1,225 | 1,469 |
Total liabilities | 73,854 | 75,259 |
Commitments and contingencies (Note 12) | ||
Stockholders' equity: | ||
Common stock, $0.001 par value, per share: Authorized shares: 120,000; Issued and outstanding: 37,566 and 37,280 shares at June 30, 2023 and December 31, 2022, respectively | 37 | 37 |
Additional paid-in capital | 772,473 | 763,688 |
Accumulated other comprehensive loss | (2,825) | (2,623) |
Accumulated deficit | (414,329) | (402,162) |
Total stockholders' equity | 355,356 | 358,940 |
Total liabilities and stockholders' equity | $ 429,210 | $ 434,199 |
CONSOLIDATED BALANCE SHEETS (Pa
CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) shares in Thousands, $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
CONSOLIDATED BALANCE SHEETS | ||
Accounts receivable, reserve for doubtful accounts | $ 442 | $ 118 |
Common stock, par value | $ 0.001 | $ 0.001 |
Common stock, authorized shares | 120,000 | 120,000 |
Common stock, shares issued | 37,566 | 37,280 |
Common stock, shares outstanding | 37,566 | 37,280 |
CONSOLIDATED STATEMENTS OF OPER
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Revenues: | ||||
Total revenues | $ 31,029 | $ 23,500 | $ 59,485 | $ 53,052 |
Costs of goods sold and services: | ||||
Total costs of goods sold and services | 11,891 | 14,789 | 23,421 | 29,782 |
Gross profit | 19,138 | 8,711 | 36,064 | 23,270 |
Operating expenses: | ||||
Research and development | 5,946 | 6,625 | 10,666 | 13,659 |
Selling, general, and administrative | 21,591 | 27,045 | 42,474 | 52,757 |
Other lease costs | 1,162 | 1,938 | ||
Restructuring | (33) | |||
Total operating expenses | 28,699 | 33,670 | 55,045 | 66,416 |
Loss from operations | (9,561) | (24,959) | (18,981) | (43,146) |
Interest income, net | 3,886 | 552 | 7,335 | 604 |
Other expense, net | (154) | (358) | (146) | (575) |
Loss before income taxes | (5,829) | (24,765) | (11,792) | (43,117) |
Income tax (expense) benefit | (235) | (137) | (375) | 62 |
Net loss | $ (6,064) | $ (24,902) | $ (12,167) | $ (43,055) |
Net loss per common share, basic (in dollars per share) | $ (0.16) | $ (0.67) | $ (0.33) | $ (1.17) |
Net loss per common share, diluted (in dollars per share) | $ (0.16) | $ (0.67) | $ (0.33) | $ (1.17) |
Weighted-average common shares outstanding, basic (in shares) | 37,494 | 36,922 | 37,411 | 36,887 |
Weighted-average common shares outstanding, diluted (in shares) | 37,494 | 36,922 | 37,411 | 36,887 |
Product revenue | ||||
Revenues: | ||||
Total revenues | $ 19,692 | $ 14,785 | $ 38,979 | $ 35,441 |
Costs of goods sold and services: | ||||
Total costs of goods sold and services | 7,236 | 9,921 | 14,269 | 20,667 |
Service revenue | ||||
Revenues: | ||||
Total revenues | 10,552 | 8,548 | 19,131 | 17,358 |
Service revenue. | ||||
Costs of goods sold and services: | ||||
Total costs of goods sold and services | 4,655 | 4,868 | 9,152 | 9,115 |
Collaboration and license revenue | ||||
Revenues: | ||||
Total revenues | 629 | 92 | 997 | 178 |
Grant revenue | ||||
Revenues: | ||||
Total revenues | $ 156 | $ 75 | $ 378 | $ 75 |
CONSOLIDATED STATEMENTS OF COMP
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS | ||||
Net loss | $ (6,064) | $ (24,902) | $ (12,167) | $ (43,055) |
Other comprehensive loss: | ||||
Foreign currency translation | (244) | (1,447) | (202) | (2,644) |
Total other comprehensive loss | (244) | (1,447) | (202) | (2,644) |
Comprehensive loss | $ (6,308) | $ (26,349) | $ (12,369) | $ (45,699) |
CONSOLIDATED STATEMENTS OF STOC
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands | Common stock | Additional paid-in capital | Accumulated other comprehensive income (loss) | Accumulated deficit | Total |
Beginning Balance at Dec. 31, 2021 | $ 37 | $ 745,936 | $ 441 | $ (305,462) | $ 440,952 |
Beginning balance (in shares) at Dec. 31, 2021 | 36,768 | ||||
Increase (Decrease) in Stockholders' Equity | |||||
Issuance of common stock under stock plans, including tax effects | 1,190 | 1,190 | |||
Issuance of common stock under stock plans, including tax effects (in shares) | 207 | ||||
Stock-based compensation expense | 9,013 | 9,013 | |||
Foreign currency translation | (2,644) | (2,644) | |||
Net loss | (43,055) | (43,055) | |||
Ending Balance at Jun. 30, 2022 | $ 37 | 756,139 | (2,203) | (348,517) | 405,456 |
Ending Balance (in shares) at Jun. 30, 2022 | 36,975 | ||||
Beginning Balance at Mar. 31, 2022 | $ 37 | 750,742 | (756) | (323,615) | 426,408 |
Beginning balance (in shares) at Mar. 31, 2022 | 36,899 | ||||
Increase (Decrease) in Stockholders' Equity | |||||
Issuance of common stock under stock plans, including tax effects | 211 | 211 | |||
Issuance of common stock under stock plans, including tax effects (in shares) | 76 | ||||
Stock-based compensation expense | 5,186 | 5,186 | |||
Foreign currency translation | (1,447) | (1,447) | |||
Net loss | (24,902) | (24,902) | |||
Ending Balance at Jun. 30, 2022 | $ 37 | 756,139 | (2,203) | (348,517) | 405,456 |
Ending Balance (in shares) at Jun. 30, 2022 | 36,975 | ||||
Beginning Balance at Dec. 31, 2022 | $ 37 | 763,688 | (2,623) | (402,162) | 358,940 |
Beginning balance (in shares) at Dec. 31, 2022 | 37,280 | ||||
Increase (Decrease) in Stockholders' Equity | |||||
Issuance of common stock under stock plans, including tax effects | 690 | 690 | |||
Issuance of common stock under stock plans, including tax effects (in shares) | 286 | ||||
Stock-based compensation expense | 8,095 | 8,095 | |||
Foreign currency translation | (202) | (202) | |||
Net loss | (12,167) | (12,167) | |||
Ending Balance at Jun. 30, 2023 | $ 37 | 772,473 | (2,825) | (414,329) | 355,356 |
Ending Balance (in shares) at Jun. 30, 2023 | 37,566 | ||||
Beginning Balance at Mar. 31, 2023 | $ 37 | 768,141 | (2,581) | (408,265) | 357,332 |
Beginning balance (in shares) at Mar. 31, 2023 | 37,424 | ||||
Increase (Decrease) in Stockholders' Equity | |||||
Issuance of common stock under stock plans, including tax effects | 139 | 139 | |||
Issuance of common stock under stock plans, including tax effects (in shares) | 142 | ||||
Stock-based compensation expense | 4,193 | 4,193 | |||
Foreign currency translation | (244) | (244) | |||
Net loss | (6,064) | (6,064) | |||
Ending Balance at Jun. 30, 2023 | $ 37 | $ 772,473 | $ (2,825) | $ (414,329) | $ 355,356 |
Ending Balance (in shares) at Jun. 30, 2023 | 37,566 |
CONSOLIDATED STATEMENT OF CASH
CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Cash flows from operating activities: | ||
Net loss | $ (12,167) | $ (43,055) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization expense | 2,845 | 2,790 |
Credit losses on accounts receivable | 324 | 581 |
Foreign currency losses | 205 | |
Operating lease right-of-use asset amortization | 1,002 | 925 |
Stock-based compensation expense | 8,095 | 9,013 |
Deferred income taxes | 343 | |
Loss on disposal of fixed assets | 6 | |
Changes in assets and liabilities: | ||
Accounts receivable | (5,750) | 3,479 |
Inventory | (1,181) | 180 |
Prepaid expenses and other assets | (527) | 960 |
Other non-current assets | (965) | 2 |
Accounts payable | (631) | (3,220) |
Accrued compensation and benefits, accrued expenses and other current liabilities | (1,326) | (4,387) |
Deferred revenue | 1,666 | 6,228 |
Operating lease liabilities | (730) | (3,128) |
Other non-current liabilities | (72) | (9) |
Net cash used in operating activities | (8,869) | (29,635) |
Cash flows from investing activities: | ||
Purchases of property and equipment | (784) | (6,454) |
Proceeds from RADx grant on assets purchased | 520 | |
Net cash used in investing activities | (784) | (5,934) |
Cash flows from financing activities: | ||
Proceeds from common stock issued under stock plans | 777 | 1,190 |
Payments for employee taxes on units withheld | (87) | |
Net cash provided by financing activities | 690 | 1,190 |
Net decrease in cash, cash equivalents, and restricted cash | (8,963) | (34,379) |
Effect of exchange rate changes on cash, cash equivalents, and restricted cash | (163) | (776) |
Cash, cash equivalents, and restricted cash at beginning of period | 341,337 | 399,042 |
Cash, cash equivalents, and restricted cash at end of period | 332,211 | 363,887 |
Supplemental disclosure of cash flow information: | ||
Cash paid for taxes | 502 | |
Operating lease right-of-use assets obtained in exchange for lease liabilities | $ 22,376 | |
Shares received in exchange for license of intellectual property (Note 3) | $ 1,000 |
Organization and Nature of Busi
Organization and Nature of Business | 6 Months Ended |
Jun. 30, 2023 | |
Organization and Nature of Business | |
Organization and Nature of Business | QUANTERIX CORPORATION NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (unaudited) Note 1. Organization and Nature of Business Quanterix Corporation (“Quanterix” or the “Company”) is a life sciences company that has developed next generation, ultra-sensitive digital immunoassay platforms that advance precision health for life sciences research and diagnostics. The Company’s platforms are based on its proprietary digital “Simoa” detection technology. The Company’s Simoa bead-based and planar array platforms enable customers to reliably detect protein biomarkers in extremely low concentrations in blood, serum, and other fluids that, in many cases, are undetectable using conventional, analog immunoassay technologies, and also allow researchers to define and validate the function of novel protein biomarkers that are only present in very low concentrations. The Company is currently focusing on protein detection, but its Simoa platforms have also demonstrated applicability across other testing applications, including detection of nucleic acids and small molecules. The Company also provides contract research services for customers through its CLIA-certified Accelerator Laboratory. The Accelerator Laboratory provides customers with access to Simoa technology and supports multiple projects and services, including sample testing, homebrew assay development, and custom assay development. To date, the Company has completed over 2,000 projects for more than 450 customers from all over the world using its Simoa platforms. |
Significant Accounting Policies
Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2023 | |
Significant Accounting Policies | |
Significant Accounting Policies | Note 2. Significant Accounting Policies Basis of Presentation These Consolidated Financial Statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 6, 2023. Since the date of that filing, there have been no changes or updates to the Company’s significant accounting policies, other than those described below. The Company’s fiscal year is the twelve-month period from January 1 through December 31. Use of Estimates The preparation of the Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets, liabilities, revenues, and expenses reported and disclosures in the financial statements and accompanying notes. Such estimates include, but are not limited to, revenue recognition, valuation of inventory, leases, valuation of intangible and other long-lived assets, recoverability of deferred tax assets, ongoing impairment reviews, and stock-based compensation expense. The Company bases its estimates on historical experience, known trends, market specific information, or other relevant factors it believes to be reasonable. On an ongoing basis, management evaluates its estimates and changes in estimates are recorded in the period in which they become known. Actual results may differ from these estimates. Foreign Currency The functional currency of the Company’s subsidiaries is their respective local currencies. These subsidiary financial statements are translated into U.S. dollars using the period-end exchange rates for assets and liabilities, average exchange rates during the corresponding period for revenue and expenses, and historical rates for equity. The effects of foreign currency translation adjustments are recorded in accumulated other comprehensive loss within stockholders’ equity on the Consolidated Balance Sheets. Foreign currency transaction gains (losses) are included in other income (expense), net on the Consolidated Statements of Operations. Foreign exchange losses were not material during the six months ended June 30, 2023, and were $0.4 million during the six months ended 2022. Principles of Consolidation The Consolidated Financial Statements include the accounts of Quanterix and its wholly-owned subsidiaries. All intercompany transactions have been eliminated in consolidation. In accordance with Accounting Standards Codification (“ASC”) 810 – Consolidation Variable Interest Entities Presentation of Restricted Cash The following table summarizes the period ending cash and cash equivalents as presented on the Consolidated Balance Sheets and the total cash, cash equivalents, and restricted cash as presented on the Consolidated Statements of Cash Flows (in thousands): As of June 30, 2023 2022 Cash and cash equivalents $ 329,525 $ 361,293 Restricted cash (1) 2,686 2,594 Cash, cash equivalents, and restricted cash $ 332,211 $ 363,887 (1) Restricted cash consists of collateral for a letter of credit issued as security for several of the Company’s leased facilities and to secure the Company’s corporate credit card program. The short-term or long-term classification is determined in accordance with the expiration of the underlying letter of credit and security. Recent Accounting Pronouncements There are no new accounting pronouncements issued or effective in the current or future periods that are expected to have a material impact on the Company’s Consolidated Financial Statements or accompanying notes. |
Revenue and Related Matters
Revenue and Related Matters | 6 Months Ended |
Jun. 30, 2023 | |
Revenue and Related Matters | |
Revenue and Related Matters | Note 3. Revenue and Related Matters Disaggregated Revenue The following tables disaggregate the Company’s revenue from contracts with customers by revenue type and geography (based on the location products and services are consumed) (in thousands): Three Months Ended June 30, 2023 Three Months Ended June 30, 2022 North America EMEA Asia Pacific Total North America EMEA Asia Pacific Total Product revenue Instruments $ 1,042 $ 971 $ 1,473 $ 3,486 $ 2,473 $ 2,127 $ 1,004 $ 5,604 Consumable and other products 9,811 4,547 1,848 16,206 4,719 3,588 874 9,181 Total $ 10,853 $ 5,518 $ 3,321 $ 19,692 $ 7,192 $ 5,715 $ 1,878 $ 14,785 Service revenue Service-type warranties $ 1,559 $ 753 $ 153 $ 2,465 $ 1,320 $ 688 $ 124 $ 2,132 Research services 6,321 711 453 7,485 5,511 316 8 5,835 Other services 372 219 11 602 317 237 27 581 Total $ 8,252 $ 1,683 $ 617 $ 10,552 $ 7,148 $ 1,241 $ 159 $ 8,548 Collaboration and license revenue $ 629 $ — $ — $ 629 $ 43 $ 49 $ — $ 92 Grant revenue $ 156 $ — $ — $ 156 $ 75 $ — $ — $ 75 Total revenues $ 19,890 $ 7,201 $ 3,938 $ 31,029 $ 14,458 $ 7,005 $ 2,037 $ 23,500 Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 North America EMEA Asia Pacific Total North America EMEA Asia Pacific Total Product revenue Instruments $ 3,186 $ 2,952 $ 2,607 $ 8,745 $ 4,638 $ 4,173 $ 3,015 $ 11,826 Consumable and other products 17,268 9,487 3,479 30,234 13,552 8,014 2,049 23,615 Total $ 20,454 $ 12,439 $ 6,086 $ 38,979 $ 18,190 $ 12,187 $ 5,064 $ 35,441 Service revenue Service-type warranties $ 3,116 $ 1,459 $ 288 $ 4,863 $ 2,603 $ 1,347 $ 216 $ 4,166 Research services 11,510 945 568 13,023 11,607 447 21 12,075 Other services 754 476 15 1,245 601 448 68 1,117 Total $ 15,380 $ 2,880 $ 871 $ 19,131 $ 14,811 $ 2,242 $ 305 $ 17,358 Collaboration and license revenue $ 997 $ — $ — $ 997 $ 43 $ 83 $ 52 $ 178 Grant revenue $ 378 $ — $ — $ 378 $ 75 $ — $ — $ 75 Total revenues $ 37,209 $ 15,319 $ 6,957 $ 59,485 $ 33,119 $ 14,512 $ 5,421 $ 53,052 For each of the three and six months ended June 30, 2023, one customer accounted for more than 10% of the Company’s total revenues. At June 30, 2023, one customer accounted for more than 10% of the Company’s gross accounts receivable. Product Revenue UltraDx On May 26, 2022, the Company and UltraDx Limited (“UltraDx”), a company formed by ARCH Venture Partners (“ARCH”), entered into an agreement (the “UltraDx Agreement). Under the UltraDx Agreement, the Company agreed to supply UltraDx with HD-X instruments (both fully assembled and disassembled), assays and assay components, and granted a co-exclusive license to manufacture, seek Chinese regulatory approval of (including performance of any necessary research and development activities), and commercialize, HD-X instruments assembled in China and related assays in the Chinese neurological in vitro diagnostic market. Refer to Note 13 – Related Party Transactions The Company determined that the instruments, components, and licenses formed a single, combined performance obligation. The consideration due to the Company included (1) cash proceeds of $1.9 million, which was received and recognized as revenue in the third quarter of 2022 when the instruments, components, and licenses were delivered to and paid by UltraDx, and (2) contingent, non-cash consideration in the form of ordinary shares of UltraDx with a deemed fair value of $1.0 million. The issuance of the shares was contingent on UltraDx completing a preferred share financing under the terms and conditions in the UltraDx Agreement. Given the uncertainty of the completion of the preferred share financing, the Company concluded that the non-cash consideration related to the ordinary shares was variable consideration that was fully constrained at contract inception. During the three months ended June 30, 2023, UltraDx completed the qualified preferred share financing and issued to the Company one million ordinary shares with a total fair value of $1.0 million. Refer to Note 5 – Fair Value of Financial Instruments Variable Interest Entities for additional information on the Company’s investment interests in UltraDx as a result of the share issuance. During the three and six months ended June 30, 2023, the Company recognized $1.4 million of revenue, which includes the one-time revenue from the receipt of the UltraDx shares. During the three and six months ended June 30, 2022, no revenue was recognized under the UltraDx Agreement. Service Revenue Eli Lilly and Company On February 25, 2022, the Company entered into a Master Collaboration Agreement with Eli Lilly and Company (“Lilly”) establishing a framework for future projects focused on the development of Simoa immunoassays (the “Lilly Collaboration Agreement”). The Company also entered into a statement of work under the Lilly Collaboration Agreement to perform assay research and development services within the field of Alzheimer’s disease. In connection with the Lilly Collaboration Agreement, the Company received a non-refundable up-front payment of $5.0 million during the first quarter of 2022, which was recognized over a one-year period. In addition, under the statement of work, the Company receives $1.5 million per calendar quarter, which began in the first quarter of 2022. The statement of work automatically renews on a quarterly basis until Lilly provides a termination notice in accordance with the terms of the Lilly Collaboration Agreement. As of June 30, 2023, the Lilly Collaboration Agreement and the statement of work were still in effect. Concurrent with the execution of the Lilly Collaboration Agreement, the Company entered into a Technology License Agreement (the “Lilly License”) under which Lilly granted the Company a non-exclusive license to Lilly’s proprietary pTau217 antibody technology for use in research use only products and services and future in vitro diagnostics applications within the field of Alzheimer’s disease. In consideration of the Lilly License, the Company paid an upfront fee, is required to make milestone payments based on the achievement of predetermined regulatory and commercial events, and will pay royalties on net sales of licensed products. The Company recognized revenue from the Lilly Collaboration Agreement of $1.5 million and $3.0 million during the three and six months ended June 30, 2023, respectively, and $2.7 million and $5.4 million during the three and six months ended June 30, 2022, respectively. Collaboration and License Revenue Abbott Laboratories On September 29, 2020, the Company and Abbott Laboratories (“Abbott”) entered into a Non-Exclusive License Agreement (the “Abbott License Agreement”). Under the terms of the Abbott License Agreement, the Company granted Abbott a non-exclusive, worldwide, royalty-bearing license, without the right to sublicense, under the Company’s bead-based single molecule detection patent (the “Licensed Patents”) in the field of in vitro diagnostics. Abbott agreed to pay the Company an initial license fee of $10.0 million in connection with the execution of the Abbott License Agreement, which was recognized as license revenue during 2020. Abbott also agreed to pay the Company milestone fees, subject to the achievement by Abbott of certain development, regulatory, and commercialization milestones and low single-digit royalties on net sales of licensed products. The Abbott License Agreement will continue until expiration of the last-to-expire licensed patent, or the agreement is earlier terminated. Under the terms of the Abbott License Agreement, the Company and Abbott each have the right to terminate the agreement for uncured material breach by, or insolvency of, the other party. Abbott may also terminate the Abbott License Agreement at any time, without cause, upon 60 days’ notice. During the three and six months ended June 30, 2023, the Company recognized $0.5 million of one-time revenue related to the expiration of a previously paid for option to expand the scope of the Abbott License Agreement. Grant Revenue The Company recognizes grant revenue after funding is committed and as each grant’s related activities are performed. The timing of revenue recognition and receipt of funding varies by grant and can be independent from performance of the related activities, such as an upfront payment of the award value, or subsequent to the Company’s requests for reimbursement for already performed activities (subject to the approval of the granting organization), as further described below. NIH Grant On September 21, 2022, the Company and the National Institutes of Health (the “NIH”) entered into a contract (the “NIH Grant”) with a total award value of $1.7 million. The NIH is an agency of the U.S. Department of Health and Human Services and granted the Company funding in support of the development of certain point-of-care diagnostic technologies through collaborative efforts. Grant funding is to be used solely for activities related to the point-of-care diagnostic device development project and the contract period runs through August 2025. Receipt of the award value occurs throughout the term of the contract period and after the Company submits for reimbursement of activities related to the grant. As of June 30, 2023, the Company had not received any of the award value. During the three and six months ended June 30, 2023, grant revenue recognized and research and development expenses incurred were immaterial. ADDF Grant On March 24, 2022, the Company and the Alzheimer’s Drug Discovery Foundation (the “ADDF”) entered into a contract (the “ADDF Grant”) with a total funding value of $2.3 million. The ADDF is a charitable venture philanthropy entity that granted the Company funding in support of certain activities for the development of an in vitro diagnostic test for early detection of Alzheimer's disease. The ADDF Grant restricts the Company’s use of the granted funds solely for activities related to the Company’s Alzheimer’s diagnostic test development project and the contract period runs through June 2024. Receipt of the contract funding was subject to achievement of pre-defined milestones, and as of June 30, 2023, the Company had received the total funding value of $2.3 million. During the three and six months ended June 30, 2023 and 2022, grant revenue recognized and research and development expenses incurred were immaterial. RADx Grant On September 29, 2020, the Company entered into a contract with the NIH under its Rapid Acceleration of Diagnostics (“RADx”) program (the “RADx Grant”), with a total award value of $18.2 million. The RADx Grant was to accelerate the continued development, scale-up, and deployment of the novel SARS-CoV-2 antigen detection test using the Company’s Simoa technology. Grant funding was used to expand assay kit manufacturing capacity and commercial deployment readiness, and the contract ran through the final milestone on May 31, 2022. Receipt of the award value occurred throughout the term of the contract period and after the Company submitted for reimbursement of activities related to the grant. During the three months ended June 30, 2022, the Company received $0.5 million which represented the final and total funding value of the $18.2 million award. During both the three and six months ended June 30, 2022, the Company recognized no grant revenue and incurred no research and development expenses. As of June 30, 2022, the Company had no future obligations under the RADx Grant. Contract Assets and Liabilities There were no contract assets of as June 30, 2023 or December 31, 2022. Deferred Revenue The Company refers to contract liabilities as deferred revenue on the Consolidated Balance Sheets . Remaining Performance Obligations As of June 30, 2023, the aggregate amount of transaction price allocated to performance obligations that have not yet been satisfied, or are partially satisfied, was $11.7 million. Of the performance obligations not yet satisfied or partially satisfied, $10.4 million is expected to be recognized as revenue in the next 12 months, with the remainder Costs to Obtain a Contract The Company capitalizes commissions paid to its sales representatives and related fringe benefits costs that are incremental to obtaining customer contracts. These costs are included in prepaid expenses and other current assets on the Consolidated Balance Sheets. Changes in costs to obtain a contract were as follows (in thousands): 2023 2022 Balance at December 31 of prior year $ 377 $ 440 Deferral of costs to obtain a contract 335 632 Amortization of costs to obtain a contract (333) (662) Balance at June 30 $ 379 $ 410 Costs to obtain a contract are amortized to earnings over the estimated life of the contract and are recorded in cost of goods sold and selling, general, and administrative expense on the Consolidated Statements of Operations. The Company evaluates potential impairment of these amounts at each balance sheet date, and no related impairments were recorded during the six months ended June 30, 2023 or 2022. |
Allowance for Credit Losses
Allowance for Credit Losses | 6 Months Ended |
Jun. 30, 2023 | |
Allowance for Credit Losses | |
Allowance for Credit Losses | Note 4. Allowance for Credit Losses The Company is exposed to credit losses primarily through accounts receivable from sales of its products and services. The Company’s expected credit loss allowance methodology is developed using historical collection experience, current and future economic and market conditions, and a review of the status of customers’ accounts receivable. Customers are assessed for credit worthiness upfront through a credit review, which includes analysis of customers’ financial statements when a credit rating is not available. The allowance for credit losses on accounts receivable is summarized as follows (in thousands): 2023 2022 Balance at December 31 of prior year $ 118 $ 419 Provision for expected credit losses 516 581 Write-offs and recoveries collected (192) — Balance at June 30 $ 442 $ 1,000 |
Fair value of financial instrum
Fair value of financial instruments | 6 Months Ended |
Jun. 30, 2023 | |
Fair value of financial instruments | |
Fair value of financial instruments | Note 5. Fair Value of Financial Instruments Recurring Fair Value Measurements The following tables present the Company’s fair value hierarchy for its financial assets that are measured at fair value on a recurring basis (in thousands): As of June 30, 2023 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets: Cash equivalents - money market funds $ 312,986 $ 312,986 $ — $ — Total Financial Assets $ 312,986 $ 312,986 $ — $ — As of December 31, 2022 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets: Cash equivalents - money market funds $ 306,097 $ 306,097 $ — $ — Total Financial Assets $ 306,097 $ 306,097 $ — $ — Nonrecurring Fair Value Measurements On June 26, 2023, the Company received ordinary shares in UltraDx (refer to Note 3 – Revenue and Related Matters million upon receipt, primarily using the third-party purchase price of similar interests issued during UltraDx’s financing event that closed in the second quarter of 2023. As UltraDx is a recently formed, privately held entity, there is minimal market activity or other financial information available to determine the fair value of UltraDx’s shares and therefore this investment is considered a Level 3 financial asset. Changes in the inputs and assumptions used would have resulted in a higher or lower fair value measurement. Pursuant to ASC 321 – Investments – Equity Securities , the Company has elected the measurement alternative for equity investments without readily determinable fair values and will continue to recognize the UltraDx shares at cost, less any impairment, and adjusted for any observable price changes in orderly transactions. As of June 30, 2023 and December 31, 2022, the carrying value of the Company’s Level 3 financial assets was $1.3 million and $0.3 million, respectively. There were no changes in the carrying value of these assets during the three and six months ended June 30, 2023 and 2022. These assets are included in other non-current assets on the Consolidated Balance Sheets. Refer to Note 15 – Variable Interest Entities Other Fair Value Disclosures |
Inventory
Inventory | 6 Months Ended |
Jun. 30, 2023 | |
Inventory | |
Inventory | Note 6. Inventory Inventory, net of inventory reserves, consisted of the following (in thousands): June 30, 2023 December 31, 2022 Raw materials $ 4,966 $ 5,509 Work in process 5,520 3,362 Finished goods 7,670 7,915 Total inventory $ 18,156 $ 16,786 |
Accrued Expenses and Other Curr
Accrued Expenses and Other Current Liabilities | 6 Months Ended |
Jun. 30, 2023 | |
Accrued Expenses and Other Current Liabilities | |
Accrued Expenses and Other Current Liabilities | Note 7. Accrued Expenses and Other Current Liabilities Accrued expenses and other current liabilities consisted of the following (in thousands): June 30, 2023 December 31, 2022 Accrued professional services $ 1,853 $ 1,409 Accrued royalties 1,167 815 Accrued tax liabilities 918 172 Accrued in-transit inventory 594 21 Other accrued expenses 2,245 2,716 Total accrued expenses and other current liabilities $ 6,777 $ 5,133 |
Stock-Based Compensation
Stock-Based Compensation | 6 Months Ended |
Jun. 30, 2023 | |
Stock-Based Compensation | |
Stock-Based Compensation | Note 8. Stock-Based Compensation Stock Options Weighted-average Weighted-average remaining Aggregate Number of shares exercise price per share contractual life (in years) intrinsic value Outstanding at December 31, 2022 2,188 $ 20.69 8.1 $ 4,273 Granted 1,006 14.91 Exercised (44) 6.74 Cancelled (355) 17.11 Outstanding at June 30, 2023 2,795 $ 19.28 8.2 $ 18,118 Exercisable at June 30, 2023 918 $ 24.67 6.0 $ 3,740 Vested and expected to vest at June 30, 2023 2,795 $ 19.28 8.2 $ 18,118 Restricted Stock Units Weighted-average Weighted-average grant date fair remaining contractual Aggregate Number of shares value per share life (in years) intrinsic value Unvested RSUs at December 31, 2022 1,188 $ 21.18 9.6 $ 16,455 Granted 737 14.58 Vested (171) 30.87 Cancelled (223) 17.37 Unvested RSUs at June 30, 2023 1,531 $ 17.47 9.3 $ 34,515 Expected to convert at June 30, 2023 1,531 $ 17.47 9.3 $ 34,515 Employee Stock Purchase Plan (“ESPP”) In December 2017, the Company adopted the 2017 Employee Stock Purchase Plan (the “2017 ESPP”). The 2017 ESPP contains an “evergreen” provision, which allows for an increase in the number of shares under the plan on the first day of each fiscal year beginning with fiscal year 2018. The increase is equal to the lowest of: (i) 1% of the number of shares of common stock outstanding on the last day of the immediately preceding fiscal year and (ii) an amount determined by the Company’s Board of Directors or Compensation Committee. On January 3, 2023, the number of shares of common stock available for issuance under the 2017 ESPP was increased by 372 thousand shares. The 2017 ESPP provides for six-month offering periods commencing and ending as follows: March 1 through August 31, and September 1 through February 28. During the six months ended June 30, 2023, employees purchased 70 thousand shares of the Company’s common stock pursuant to the 2017 ESPP. Stock-Based Compensation Expense Stock-based compensation expense was recorded in the following categories on the Consolidated Statements of Operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cost of product revenue $ 200 $ 137 $ 387 $ 225 Cost of service and other revenue 258 205 608 371 Research and development 405 482 775 880 Selling, general, and administrative 3,330 4,362 6,325 7,537 Total stock-based compensation $ 4,193 $ 5,186 $ 8,095 $ 9,013 As of June 30, 2023, there was $39.8 million of total unrecognized stock-based compensation expense related to unvested RSUs and stock options, which is expected to be recognized over the remaining weighted-average vesting period of 2.9 years. The fair value of the Company’s stock options granted and purchase rights to the ESPP were estimated using the Black-Scholes valuation model with the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Stock Options: Risk-free interest rate 3.5% - 4.2% 2.7% - 3.2% 3.5% - 4.2% 1.4% - 3.2% Expected dividend yield — — — — Expected term (in years) 5.0 - 5.1 5.7 - 5.8 5.0 - 5.1 5.7 - 5.8 Expected volatility 80.9% - 82.1% 55.1% - 56.2% 71.1% - 82.1% 55.0% - 56.2% Weighted-average grant date fair value $ 11.95 $ 13.47 $ 9.62 $ 14.11 Employee Stock Purchase Plan: Risk-free interest rate 5.2% 1.1% 5.2% 0.7% - 1.1% Expected dividend yield — — — — Expected term (in years) 0.5 0.5 0.5 0.5 Expected volatility 72.8% 55.7% 72.8% - 82.5% 51.9% - 55.7% Weighted-average grant date fair value $ 2.25 $ 4.62 $ 2.24 $ 4.76 |
Net Loss Per Share
Net Loss Per Share | 6 Months Ended |
Jun. 30, 2023 | |
Net Loss Per Share | |
Net Loss Per Share | Note 9. Net Loss Per Share The following table presents the computation of basic and diluted net loss per share (in thousands, except per share data): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss $ (6,064) $ (24,902) $ (12,167) $ (43,055) Denominator: Weighted average common shares outstanding 37,494 36,922 37,411 36,887 Net loss per share, basic and diluted $ (0.16) $ (0.67) $ (0.33) $ (1.17) In periods when the Company is in a net loss position, dilutive securities are excluded from the computation of diluted earnings per share because their inclusion would have an anti-dilutive effect. Therefore, basic net loss per share is the same as diluted net loss per share. The following common share equivalents have been excluded from the calculation of diluted net loss per share (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Common stock and RSUs 1,607 928 1,557 759 Stock options 2,891 2,578 2,810 2,383 Total anti-dilutive shares 4,498 3,506 4,367 3,142 |
Income Taxes
Income Taxes | 6 Months Ended |
Jun. 30, 2023 | |
Income Taxes | |
Income Taxes | Note 10. Income Taxes The Company’s effective tax rates were 4.0% and 3.2% for the three and six months ended June 30, 2023, respectively, and 0.0% for each of the three and six months ended June 30, 2022. The income tax provision and effective tax rate is driven primarily by a valuation allowance in the United States, partially offset by income taxes in foreign jurisdictions. The Company maintains a valuation allowance on the majority of its deferred tax assets, and it has concluded that it is more likely than not that the deferred assets will not be utilized. |
Goodwill
Goodwill | 6 Months Ended |
Jun. 30, 2023 | |
Goodwill. | |
Goodwill | Note 11. Goodwill During the third quarter of 2022, the Company identified certain indicators of impairment, including a significant decline in the Company’s stock price, actions taken under the Restructuring Plan (refer to Note 14 - Restructuring ), and a reduction of forecasted sales and profitability. As a result, the Company performed a goodwill impairment test and determined its goodwill was impaired as the carrying amount of the Company’s sole reporting unit exceeded its estimated fair value. The Company concluded that its entire goodwill balance was impaired and recognized an $8.2 million non-cash impairment charge during the third quarter of 2022. As of June 30, 2023 and December 31, 2022, the Company had no remaining goodwill balance. |
Commitments and Contingencies
Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2023 | |
Commitments and Contingencies | |
Commitments and Contingencies | Note 12. Commitments and Contingencies Purchase Commitments Stratec During the year ended December 31, 2022, the Company and Stratec Consumables GmbH (“Stratec”) entered into an amendment to the supply agreement with Stratec (as amended, the “Stratec Supply Agreement”), related to the supply of discs used in Simoa bead-based instruments. As part of the Stratec Supply Agreement, the Company agreed to purchase a total of 515,000 discs to be shipped at various points starting in 2022 and continuing through 2024 at an agreed purchase price per disc. In 2022, Stratec shipped 75,000 discs to the Company and Stratec is required to ship no less than 220,000 discs in 2023. The total purchase commitment under the Stratec Supply Agreement is $3.7 million. Other Purchase Commitments The Company purchases raw materials for manufacturing operations under annual and multi-year agreements, some of which have minimum quantity requirements. Additionally, the Company enters into annual agreements for other parts of its operations. The Company’s total purchase commitments under these agreements as of June 30, 2023 was $2.6 million. License Agreements Harvard University In August 2022, the Company and Harvard University (“Harvard”) entered into a license agreement (the “Harvard License Agreement”) for certain intellectual property owned by Harvard. Pursuant to the Harvard License Agreement, the Company paid an upfront fee of $0.6 million, which was recorded in research and development expenses on the Consolidated Statements of Operations. Under this license, the Company is required to pay Harvard low single-digit royalties on net sales of products and services using the licensed technology, as well as a portion of its applicable sublicense revenues. The Company incurred no royalty expense under the Harvard License Agreement for the three and six months ended June 30, 2023, and 2022. Refer to Note 13 – Related Party Transactions Tufts University In June 2007, the Company and Tufts University (“Tufts”) entered into a license agreement (the “Tufts License Agreement”) for certain intellectual property owned by Tufts. The Tufts License Agreement, which was subsequently amended, is exclusive and sub-licensable, and will continue in effect on a country-by-country basis as long as there is a valid claim of a licensed patent in a country. The Company is contractually obligated to pay license and maintenance fees that are creditable against royalties, in addition to low single-digit royalties on direct sales and services, and a royalty on sublicense income. The Company recorded royalty expense related to the Tufts License Agreement of $0.4 million and $0.8 million during the three and six months ended June 30, 2023, respectively and $0.4 million and $0.7 million during the three and six months ended June 30, 2022, respectively. This royalty expense is recorded in cost of product revenue on the Consolidated Statements of Operations. Refer to Note 13 – Related Party Transactions Legal Contingencies The Company is subject to claims in the ordinary course of business; however, the Company is not currently a party to any pending or threatened litigation, the outcome of which would be expected to have a material adverse effect on its financial condition or results of operations. The Company accrues for contingent liabilities when losses are probable and estimable. If an estimate of a probable loss is a range and no amount within the range is more likely than any other amount in the range, the Company accrues the minimum amount of the range. Leases Future minimum lease payments under non-cancellable operating leases were as follows (in thousands): Maturity of lease liabilities As of June 30, 2023 2023 (remainder) $ 3,487 2024 7,064 2025 7,228 2026 7,408 2027 7,641 2028 7,880 Thereafter 15,741 Total lease payments $ 56,449 Less: imputed interest 13,085 Total operating lease liabilities $ 43,364 |
Related Party Transactions
Related Party Transactions | 6 Months Ended |
Jun. 30, 2023 | |
Related Party Transactions | |
Related Party Transactions | Note 13. Related Party Transactions In June 2007, the Company and Tufts entered into the Tufts License Agreement for certain intellectual property owned by Tufts (refer to Note 12 - Commitments and Contingencies A member of the Company’s Board of Directors is affiliated with Harvard and Mass General Brigham. Revenue recorded from sales of products and services to Harvard and its affiliates and to Mass General Brigham and its affiliates totaled $0.5 million and $0.7 million for the three and six months ended June 30, 2023, respectively, and was immaterial for the three and six months ended June 30, 2022. Additionally, in August 2022, the Company and Harvard entered into the Harvard License Agreement for certain intellectual property owned by Harvard (refer to Note 12 – Commitments and Contingencies Cost of product revenue and operating expenses with Harvard and its affiliates and Mass General Brigham and its affiliates for the three and six months ended June 30, 2023 and 2022 was immaterial. At June 30, 2023 and December 31, 2022, open payables to and receivable balances from Harvard and Mass General Brigham were immaterial. As discussed in Note 3 – Revenue and Related Matters |
Restructuring
Restructuring | 6 Months Ended |
Jun. 30, 2023 | |
Restructuring | |
Restructuring | Note 14. Restructuring Following a strategic review and assessment of the Company’s operations and cost structure, on August 8, 2022, the Company announced a restructuring and strategic re-alignment plan (the “Restructuring Plan”). As part of the Restructuring Plan, the Company began an assay redevelopment program with the ultimate objective of improving its ability to manufacture and deliver high-quality assays at scale. The Restructuring Plan aligns the Company’s investments to best serve the needs of its customers, focuses the Company’s innovation efforts on key platforms, and provides a foundation for the Company’s entry into translational pharma and clinical markets, which it believes will be required to access new growth categories. In accordance with the Restructuring Plan, the Company implemented a workforce reduction, which was substantially completed by the end of the third quarter of 2022. The Restructuring Plan included the elimination of 119 positions and other cost-saving measures. As a result of the Restructuring Plan, the Company performed an impairment assessment of its goodwill, long-lived assets, including operating lease right-of-use assets, and intangibles. The assessments resulted in the Company recording an impairment charge of $25.6 million during the year ended December 31, 2022. The impairment charge included (1) $16.3 million associated with the operating lease right-of-use asset and related property and equipment at leased facilities, (2) $8.2 million of goodwill (refer to Note 11 – Goodwill The following table presents the restructuring reserve and provision activity for the six months ended June 30, 2023 (in thousands): Severance and Employee Benefit Costs Balance at December 31, 2022 $ 328 Accrual adjustments (33) Cash payments (16) Foreign currency translation 5 Balance at June 30, 2023 $ 284 The Company did not have any restructuring activities during the six months ended June 30, 2022. |
Variable Interest Entities
Variable Interest Entities | 6 Months Ended |
Jun. 30, 2023 | |
Variable Interest Entities | |
Variable Interest Entities | Note 15. Variable Interest Entities The Company enters into relationships with or has investments in other entities that may be VIEs. The Company assesses the criteria in ASC 810 – Consolidation to determine if any of these entities meet the definition of a VIE and require consolidation into its financial statements. As discussed in Note 3 – Revenue and Related Matters Based on the Company’s assessments, it does not have any controlling financial interests in any VIEs, and therefore did not consolidate any VIEs into its Consolidated Financial Statements during the three and six months ended June 30, 2023 and 2022. As of June 30, 2023 and December 31, 2022, the carrying value of the Company’s investment interests in VIEs was $1.3 million and $0.3 million, respectively, which are recorded in other non-current assets on the Consolidated Balance Sheets. Fair Value of Financial Instruments Maximum exposure to losses related to these VIEs is limited to their carrying value and the Company does not have any future funding commitments to these VIEs. |
Significant Accounting Polici_2
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2023 | |
Significant Accounting Policies | |
Basis of Presentation | Basis of Presentation These Consolidated Financial Statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 6, 2023. Since the date of that filing, there have been no changes or updates to the Company’s significant accounting policies, other than those described below. The Company’s fiscal year is the twelve-month period from January 1 through December 31. |
Use of Estimates | Use of Estimates The preparation of the Consolidated Financial Statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts of assets, liabilities, revenues, and expenses reported and disclosures in the financial statements and accompanying notes. Such estimates include, but are not limited to, revenue recognition, valuation of inventory, leases, valuation of intangible and other long-lived assets, recoverability of deferred tax assets, ongoing impairment reviews, and stock-based compensation expense. The Company bases its estimates on historical experience, known trends, market specific information, or other relevant factors it believes to be reasonable. On an ongoing basis, management evaluates its estimates and changes in estimates are recorded in the period in which they become known. Actual results may differ from these estimates. |
Presentation of Restricted Cash | Presentation of Restricted Cash The following table summarizes the period ending cash and cash equivalents as presented on the Consolidated Balance Sheets and the total cash, cash equivalents, and restricted cash as presented on the Consolidated Statements of Cash Flows (in thousands): As of June 30, 2023 2022 Cash and cash equivalents $ 329,525 $ 361,293 Restricted cash (1) 2,686 2,594 Cash, cash equivalents, and restricted cash $ 332,211 $ 363,887 (1) Restricted cash consists of collateral for a letter of credit issued as security for several of the Company’s leased facilities and to secure the Company’s corporate credit card program. The short-term or long-term classification is determined in accordance with the expiration of the underlying letter of credit and security. |
Recent Accounting Pronouncements | Recent Accounting Pronouncements There are no new accounting pronouncements issued or effective in the current or future periods that are expected to have a material impact on the Company’s Consolidated Financial Statements or accompanying notes. |
Significant Accounting Polici_3
Significant Accounting Policies (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Significant Accounting Policies | |
Schedule of cash and cash equivalents | The following table summarizes the period ending cash and cash equivalents as presented on the Consolidated Balance Sheets and the total cash, cash equivalents, and restricted cash as presented on the Consolidated Statements of Cash Flows (in thousands): As of June 30, 2023 2022 Cash and cash equivalents $ 329,525 $ 361,293 Restricted cash (1) 2,686 2,594 Cash, cash equivalents, and restricted cash $ 332,211 $ 363,887 (1) Restricted cash consists of collateral for a letter of credit issued as security for several of the Company’s leased facilities and to secure the Company’s corporate credit card program. The short-term or long-term classification is determined in accordance with the expiration of the underlying letter of credit and security. |
Revenue and Related Matters (Ta
Revenue and Related Matters (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Revenue and Related Matters | |
Schedule of disaggregated revenue | The following tables disaggregate the Company’s revenue from contracts with customers by revenue type and geography (based on the location products and services are consumed) (in thousands): Three Months Ended June 30, 2023 Three Months Ended June 30, 2022 North America EMEA Asia Pacific Total North America EMEA Asia Pacific Total Product revenue Instruments $ 1,042 $ 971 $ 1,473 $ 3,486 $ 2,473 $ 2,127 $ 1,004 $ 5,604 Consumable and other products 9,811 4,547 1,848 16,206 4,719 3,588 874 9,181 Total $ 10,853 $ 5,518 $ 3,321 $ 19,692 $ 7,192 $ 5,715 $ 1,878 $ 14,785 Service revenue Service-type warranties $ 1,559 $ 753 $ 153 $ 2,465 $ 1,320 $ 688 $ 124 $ 2,132 Research services 6,321 711 453 7,485 5,511 316 8 5,835 Other services 372 219 11 602 317 237 27 581 Total $ 8,252 $ 1,683 $ 617 $ 10,552 $ 7,148 $ 1,241 $ 159 $ 8,548 Collaboration and license revenue $ 629 $ — $ — $ 629 $ 43 $ 49 $ — $ 92 Grant revenue $ 156 $ — $ — $ 156 $ 75 $ — $ — $ 75 Total revenues $ 19,890 $ 7,201 $ 3,938 $ 31,029 $ 14,458 $ 7,005 $ 2,037 $ 23,500 Six Months Ended June 30, 2023 Six Months Ended June 30, 2022 North America EMEA Asia Pacific Total North America EMEA Asia Pacific Total Product revenue Instruments $ 3,186 $ 2,952 $ 2,607 $ 8,745 $ 4,638 $ 4,173 $ 3,015 $ 11,826 Consumable and other products 17,268 9,487 3,479 30,234 13,552 8,014 2,049 23,615 Total $ 20,454 $ 12,439 $ 6,086 $ 38,979 $ 18,190 $ 12,187 $ 5,064 $ 35,441 Service revenue Service-type warranties $ 3,116 $ 1,459 $ 288 $ 4,863 $ 2,603 $ 1,347 $ 216 $ 4,166 Research services 11,510 945 568 13,023 11,607 447 21 12,075 Other services 754 476 15 1,245 601 448 68 1,117 Total $ 15,380 $ 2,880 $ 871 $ 19,131 $ 14,811 $ 2,242 $ 305 $ 17,358 Collaboration and license revenue $ 997 $ — $ — $ 997 $ 43 $ 83 $ 52 $ 178 Grant revenue $ 378 $ — $ — $ 378 $ 75 $ — $ — $ 75 Total revenues $ 37,209 $ 15,319 $ 6,957 $ 59,485 $ 33,119 $ 14,512 $ 5,421 $ 53,052 |
Schedule of changes in deferred revenue from contracts with customers | . |
Schedule of costs to obtain a contract | 2023 2022 Balance at December 31 of prior year $ 377 $ 440 Deferral of costs to obtain a contract 335 632 Amortization of costs to obtain a contract (333) (662) Balance at June 30 $ 379 $ 410 |
Allowance for Credit Losses (Ta
Allowance for Credit Losses (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Allowance for Credit Losses | |
Schedule of the allowance for credit losses | The allowance for credit losses on accounts receivable is summarized as follows (in thousands): 2023 2022 Balance at December 31 of prior year $ 118 $ 419 Provision for expected credit losses 516 581 Write-offs and recoveries collected (192) — Balance at June 30 $ 442 $ 1,000 |
Fair value of financial instr_2
Fair value of financial instruments (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Fair value of financial instruments | |
Schedule of fair value measurements | Recurring Fair Value Measurements The following tables present the Company’s fair value hierarchy for its financial assets that are measured at fair value on a recurring basis (in thousands): As of June 30, 2023 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets: Cash equivalents - money market funds $ 312,986 $ 312,986 $ — $ — Total Financial Assets $ 312,986 $ 312,986 $ — $ — As of December 31, 2022 Total Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Financial assets: Cash equivalents - money market funds $ 306,097 $ 306,097 $ — $ — Total Financial Assets $ 306,097 $ 306,097 $ — $ — |
Inventory (Tables)
Inventory (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Inventory | |
Summary of inventory | Inventory, net of inventory reserves, consisted of the following (in thousands): June 30, 2023 December 31, 2022 Raw materials $ 4,966 $ 5,509 Work in process 5,520 3,362 Finished goods 7,670 7,915 Total inventory $ 18,156 $ 16,786 |
Accrued Expenses and Other Cu_2
Accrued Expenses and Other Current Liabilities (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Accrued Expenses and Other Current Liabilities | |
Summary of Accrued expenses and other current liabilities | Accrued expenses and other current liabilities consisted of the following (in thousands): June 30, 2023 December 31, 2022 Accrued professional services $ 1,853 $ 1,409 Accrued royalties 1,167 815 Accrued tax liabilities 918 172 Accrued in-transit inventory 594 21 Other accrued expenses 2,245 2,716 Total accrued expenses and other current liabilities $ 6,777 $ 5,133 |
Stock-Based Compensation (Table
Stock-Based Compensation (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Stock-Based Compensation | |
Summary of share-based compensation expense for all stock awards | Stock-based compensation expense was recorded in the following categories on the Consolidated Statements of Operations (in thousands): Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Cost of product revenue $ 200 $ 137 $ 387 $ 225 Cost of service and other revenue 258 205 608 371 Research and development 405 482 775 880 Selling, general, and administrative 3,330 4,362 6,325 7,537 Total stock-based compensation $ 4,193 $ 5,186 $ 8,095 $ 9,013 |
Summary of stock option activity | Stock Options Weighted-average Weighted-average remaining Aggregate Number of shares exercise price per share contractual life (in years) intrinsic value Outstanding at December 31, 2022 2,188 $ 20.69 8.1 $ 4,273 Granted 1,006 14.91 Exercised (44) 6.74 Cancelled (355) 17.11 Outstanding at June 30, 2023 2,795 $ 19.28 8.2 $ 18,118 Exercisable at June 30, 2023 918 $ 24.67 6.0 $ 3,740 Vested and expected to vest at June 30, 2023 2,795 $ 19.28 8.2 $ 18,118 |
Summary of restricted stock units activity | Restricted Stock Units Weighted-average Weighted-average grant date fair remaining contractual Aggregate Number of shares value per share life (in years) intrinsic value Unvested RSUs at December 31, 2022 1,188 $ 21.18 9.6 $ 16,455 Granted 737 14.58 Vested (171) 30.87 Cancelled (223) 17.37 Unvested RSUs at June 30, 2023 1,531 $ 17.47 9.3 $ 34,515 Expected to convert at June 30, 2023 1,531 $ 17.47 9.3 $ 34,515 |
Summary of fair value of the Company's stock options granted and purchase rights to the ESPP | The fair value of the Company’s stock options granted and purchase rights to the ESPP were estimated using the Black-Scholes valuation model with the following assumptions: Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Stock Options: Risk-free interest rate 3.5% - 4.2% 2.7% - 3.2% 3.5% - 4.2% 1.4% - 3.2% Expected dividend yield — — — — Expected term (in years) 5.0 - 5.1 5.7 - 5.8 5.0 - 5.1 5.7 - 5.8 Expected volatility 80.9% - 82.1% 55.1% - 56.2% 71.1% - 82.1% 55.0% - 56.2% Weighted-average grant date fair value $ 11.95 $ 13.47 $ 9.62 $ 14.11 Employee Stock Purchase Plan: Risk-free interest rate 5.2% 1.1% 5.2% 0.7% - 1.1% Expected dividend yield — — — — Expected term (in years) 0.5 0.5 0.5 0.5 Expected volatility 72.8% 55.7% 72.8% - 82.5% 51.9% - 55.7% Weighted-average grant date fair value $ 2.25 $ 4.62 $ 2.24 $ 4.76 |
Net Loss Per Share (Tables)
Net Loss Per Share (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Net Loss Per Share | |
Schedule of basic and diluted shares | Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Numerator: Net loss $ (6,064) $ (24,902) $ (12,167) $ (43,055) Denominator: Weighted average common shares outstanding 37,494 36,922 37,411 36,887 Net loss per share, basic and diluted $ (0.16) $ (0.67) $ (0.33) $ (1.17) |
Schedule of common share equivalents have been excluded from the calculation of diluted net loss per share | Three Months Ended June 30, Six Months Ended June 30, 2023 2022 2023 2022 Common stock and RSUs 1,607 928 1,557 759 Stock options 2,891 2,578 2,810 2,383 Total anti-dilutive shares 4,498 3,506 4,367 3,142 |
Commitments and contingencies (
Commitments and contingencies (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Commitments and Contingencies | |
Schedule of future minimum lease payments | Maturity of lease liabilities As of June 30, 2023 2023 (remainder) $ 3,487 2024 7,064 2025 7,228 2026 7,408 2027 7,641 2028 7,880 Thereafter 15,741 Total lease payments $ 56,449 Less: imputed interest 13,085 Total operating lease liabilities $ 43,364 |
Restructuring (Tables)
Restructuring (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Restructuring | |
Schedule of rollforward of the restructuring reserve and provision activity | The following table presents the restructuring reserve and provision activity for the six months ended June 30, 2023 (in thousands): Severance and Employee Benefit Costs Balance at December 31, 2022 $ 328 Accrual adjustments (33) Cash payments (16) Foreign currency translation 5 Balance at June 30, 2023 $ 284 |
Organization and Nature of Bu_2
Organization and Nature of Business (Details) | Jun. 30, 2023 project customer |
Organization and Nature of Business | |
Entity Number of Projected completed | project | 2,000 |
Minimum | |
Organization and Nature of Business | |
Entity Number of Customers Served | customer | 450 |
Significant Accounting Polici_4
Significant Accounting Policies - Presentation of Restricted Cash (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | Jun. 30, 2022 | Dec. 31, 2021 |
Cash and Cash equivalents | ||||
Cash and cash equivalents | $ 329,525 | $ 338,740 | ||
Restricted cash (1) | 2,686 | |||
Cash, cash equivalents, and restricted cash | $ 332,211 | $ 341,337 | $ 363,887 | $ 399,042 |
Revenue and Related Matters - D
Revenue and Related Matters - Disaggregated revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Service Revenue | ||||
Total revenues | $ 31,029 | $ 23,500 | $ 59,485 | $ 53,052 |
NA | ||||
Service Revenue | ||||
Total revenues | 19,890 | 14,458 | 37,209 | 33,119 |
EMEA | ||||
Service Revenue | ||||
Total revenues | 7,201 | 7,005 | 15,319 | 14,512 |
Asia Pacific | ||||
Service Revenue | ||||
Total revenues | 3,938 | 2,037 | 6,957 | 5,421 |
Product revenue | ||||
Service Revenue | ||||
Total revenues | 19,692 | 14,785 | 38,979 | 35,441 |
Product revenue | NA | ||||
Service Revenue | ||||
Total revenues | 10,853 | 7,192 | 20,454 | 18,190 |
Product revenue | EMEA | ||||
Service Revenue | ||||
Total revenues | 5,518 | 5,715 | 12,439 | 12,187 |
Product revenue | Asia Pacific | ||||
Service Revenue | ||||
Total revenues | 3,321 | 1,878 | 6,086 | 5,064 |
Instruments | ||||
Service Revenue | ||||
Total revenues | 3,486 | 5,604 | 8,745 | 11,826 |
Instruments | NA | ||||
Service Revenue | ||||
Total revenues | 1,042 | 2,473 | 3,186 | 4,638 |
Instruments | EMEA | ||||
Service Revenue | ||||
Total revenues | 971 | 2,127 | 2,952 | 4,173 |
Instruments | Asia Pacific | ||||
Service Revenue | ||||
Total revenues | 1,473 | 1,004 | 2,607 | 3,015 |
Consumable and other products | ||||
Service Revenue | ||||
Total revenues | 16,206 | 9,181 | 30,234 | 23,615 |
Consumable and other products | NA | ||||
Service Revenue | ||||
Total revenues | 9,811 | 4,719 | 17,268 | 13,552 |
Consumable and other products | EMEA | ||||
Service Revenue | ||||
Total revenues | 4,547 | 3,588 | 9,487 | 8,014 |
Consumable and other products | Asia Pacific | ||||
Service Revenue | ||||
Total revenues | 1,848 | 874 | 3,479 | 2,049 |
Service revenue | ||||
Service Revenue | ||||
Total revenues | 10,552 | 8,548 | 19,131 | 17,358 |
Service revenue | NA | ||||
Service Revenue | ||||
Total revenues | 8,252 | 7,148 | 15,380 | 14,811 |
Service revenue | EMEA | ||||
Service Revenue | ||||
Total revenues | 1,683 | 1,241 | 2,880 | 2,242 |
Service revenue | Asia Pacific | ||||
Service Revenue | ||||
Total revenues | 617 | 159 | 871 | 305 |
Research services | ||||
Service Revenue | ||||
Total revenues | 7,485 | 5,835 | 13,023 | 12,075 |
Research services | NA | ||||
Service Revenue | ||||
Total revenues | 6,321 | 5,511 | 11,510 | 11,607 |
Research services | EMEA | ||||
Service Revenue | ||||
Total revenues | 711 | 316 | 945 | 447 |
Research services | Asia Pacific | ||||
Service Revenue | ||||
Total revenues | 453 | 8 | 568 | 21 |
Other services | ||||
Service Revenue | ||||
Total revenues | 602 | 581 | 1,245 | 1,117 |
Other services | NA | ||||
Service Revenue | ||||
Total revenues | 372 | 317 | 754 | 601 |
Other services | EMEA | ||||
Service Revenue | ||||
Total revenues | 219 | 237 | 476 | 448 |
Other services | Asia Pacific | ||||
Service Revenue | ||||
Total revenues | 11 | 27 | 15 | 68 |
Service-type warranties | ||||
Service Revenue | ||||
Total revenues | 2,465 | 2,132 | 4,863 | 4,166 |
Service-type warranties | NA | ||||
Service Revenue | ||||
Total revenues | 1,559 | 1,320 | 3,116 | 2,603 |
Service-type warranties | EMEA | ||||
Service Revenue | ||||
Total revenues | 753 | 688 | 1,459 | 1,347 |
Service-type warranties | Asia Pacific | ||||
Service Revenue | ||||
Total revenues | 153 | 124 | 288 | 216 |
Collaboration and license revenue | ||||
Service Revenue | ||||
Total revenues | 629 | 92 | 997 | 178 |
Collaboration and license revenue | NA | ||||
Service Revenue | ||||
Total revenues | 629 | 43 | 997 | 43 |
Collaboration and license revenue | EMEA | ||||
Service Revenue | ||||
Total revenues | 49 | 83 | ||
Collaboration and license revenue | Asia Pacific | ||||
Service Revenue | ||||
Total revenues | 52 | |||
Grant revenue | ||||
Service Revenue | ||||
Total revenues | 156 | 75 | 378 | 75 |
Grant revenue | NA | ||||
Service Revenue | ||||
Total revenues | $ 156 | $ 75 | $ 378 | $ 75 |
Revenue and Related Matters - S
Revenue and Related Matters - Service Revenue (Details) $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2023 USD ($) customer | Jun. 30, 2022 USD ($) | Mar. 31, 2022 USD ($) | Jun. 30, 2023 USD ($) customer | Jun. 30, 2022 USD ($) | Dec. 31, 2022 USD ($) | |
Service Revenue | ||||||
Revenue | $ 31,029 | $ 23,500 | $ 59,485 | $ 53,052 | ||
Accounts Receivable | ||||||
Service Revenue | ||||||
Number Of Customers With High Percent Of Gross Accounts Receivable | customer | 1 | 1 | ||||
Customer Concentration Risk | ||||||
Service Revenue | ||||||
Threshold limit used for calculating concentration risk percentage | 10% | |||||
Customer Concentration Risk | Revenue. | ||||||
Service Revenue | ||||||
Number Of Customers With High Percent Of Total Revenue | customer | 1 | 1 | ||||
Threshold limit used for calculating concentration risk percentage | 10% | 10% | ||||
Service revenue | ||||||
Service Revenue | ||||||
Revenue | $ 10,552 | 8,548 | $ 19,131 | 17,358 | ||
Collaboration agreement | Service revenue | ||||||
Service Revenue | ||||||
Revenue | $ 1,500 | $ 2,700 | $ 3,000 | $ 5,400 | ||
Master collaboration agreement | Eli Lilly | ||||||
Service Revenue | ||||||
Non-refundable up-front payment received | $ 5,000 | |||||
Statement of works agreement | Eli Lilly | ||||||
Service Revenue | ||||||
Collaborative arrangement payment received per quarter | $ 1,500 |
Revenue and Related Matters - C
Revenue and Related Matters - Collaboration and license arrangements (Details) - USD ($) $ in Thousands, shares in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2020 | |
Collaboration and license arrangements | ||||||
Revenue | $ 31,029 | $ 23,500 | $ 59,485 | $ 53,052 | ||
UltraDx | ||||||
Collaboration and license arrangements | ||||||
Revenue | $ 1,400 | 0 | $ 1,400 | 0 | ||
Consideration on collaboration activities | $ 1,900 | |||||
Shares amount received | $ 1,000 | |||||
Number of contingent consideration collaboration | 1 | |||||
Total fair value | $ 1,000 | |||||
Abbot license agreement | ||||||
Collaboration and license arrangements | ||||||
Number of days notice to terminate agreement | 60 days | |||||
Initial license fee receivable | $ 10,000 | |||||
Revenue | 500 | $ 500 | ||||
Collaboration and license revenue | ||||||
Collaboration and license arrangements | ||||||
Revenue | $ 629 | $ 92 | $ 997 | $ 178 |
Revenue and Related Matters - G
Revenue and Related Matters - Grant revenue (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||||
Sep. 21, 2022 | Mar. 24, 2022 | Sep. 29, 2020 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Total revenues | $ 31,029 | $ 23,500 | $ 59,485 | $ 53,052 | |||
Research and Development Expense | 5,946 | 6,625 | 10,666 | 13,659 | |||
Deferred revenue | (1,666) | (6,228) | |||||
RADx WP2 | |||||||
Contract value | $ 18,200 | 18,200 | |||||
Contract Payment Received | 500 | ||||||
Research and Development Expense | 0 | 0 | |||||
ADDF | |||||||
Contract value | $ 2,300 | 2,300 | |||||
National Institutes of Health | |||||||
Contract value | $ 1,700 | ||||||
Grant revenue | |||||||
Total revenues | $ 156 | 75 | 378 | 75 | |||
Grant revenue | RADx WP2 | |||||||
Total revenues | $ 0 | $ 0 | $ 0 |
Revenue and Related Matters -_2
Revenue and Related Matters - Contract Assets and Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Revenue and Related Matters | ||
Contract with Customer, Asset, after Allowance for Credit Loss | $ 0 | $ 0 |
Revenue and Related Matters -_3
Revenue and Related Matters - Deferred Revenue (Details) - USD ($) $ in Millions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2023 | Dec. 31, 2022 | |
Revenue and Related Matters | ||
Deferred Revenue, Revenue Recognized | $ 4.9 | $ 3.6 |
Revenue and Related Matters - R
Revenue and Related Matters - Remaining Performance Obligations (Details) $ in Millions | Jun. 30, 2023 USD ($) |
Transaction Price Allocated to Remaining Performance Obligations | |
Amount of transaction price allocated to performance obligations | $ 11.7 |
Undelivered licenses of intellectual property | |
Transaction Price Allocated to Remaining Performance Obligations | |
Amount of transaction price allocated to performance obligations | 10.4 |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-07-01 | |
Transaction Price Allocated to Remaining Performance Obligations | |
Amount of transaction price allocated to performance obligations | $ 10.4 |
Performance obligation satisfaction period | 12 months |
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-07-01 | |
Transaction Price Allocated to Remaining Performance Obligations | |
Amount of transaction price allocated to performance obligations | $ 1.3 |
Performance obligation satisfaction period | 24 months |
Revenue and Related Matters -_4
Revenue and Related Matters - Costs to obtain a contract (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Change in the balance of costs to obtain a contract | ||
Balance at beginning of period | $ 377 | $ 440 |
Deferral of costs to obtain a contract | 335 | 632 |
Amortization of costs to obtain a contract | (333) | (662) |
Balance at end of period | 379 | 410 |
Impairment loss | $ 0 | $ 0 |
Allowance for Credit Losses (De
Allowance for Credit Losses (Details) - USD ($) $ in Thousands | 6 Months Ended | |
Jun. 30, 2023 | Jun. 30, 2022 | |
Allowance for Credit Losses | ||
Beginning Balance | $ 118 | $ 419 |
Provision for expected credit losses | 516 | 581 |
Write-offs and recoveries collected | (192) | |
Ending Balance | $ 442 | $ 1,000 |
Fair value of financial instr_3
Fair value of financial instruments (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] | ||
Total Financial Assets | $ 312,986 | $ 306,097 |
Money market funds | ||
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] | ||
Cash equivalents - money market funds | 312,986 | 306,097 |
Level 1 | ||
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] | ||
Total Financial Assets | 312,986 | 306,097 |
Level 1 | Money market funds | ||
Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract] | ||
Cash equivalents - money market funds | $ 312,986 | $ 306,097 |
Fair value of financial instr_4
Fair value of financial instruments - Changes in Level 3 Financial Instruments (Details) - USD ($) $ in Millions | Jun. 23, 2023 | Jun. 30, 2023 | Dec. 31, 2022 |
Changes in the Company's Level 3 financial instruments | |||
Receipt of ordinary shares of UltraDx (Note 13) | $ 1 | ||
Fair value | $ 1.3 | $ 0.3 |
Inventory (Details)
Inventory (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Inventory | ||
Raw Materials | $ 4,966 | $ 5,509 |
Work in process | 5,520 | 3,362 |
Finished goods | 7,670 | 7,915 |
Total inventory | $ 18,156 | $ 16,786 |
Accrued Expenses and Other Cu_3
Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Accrued Expenses and Other Current Liabilities | ||
Accrued professional services | $ 1,853 | $ 1,409 |
Accrued royalties | 1,167 | 815 |
Accrued tax liabilities | 918 | 172 |
Accrued in-transit inventory | 594 | 21 |
Other accrued expenses | 2,245 | 2,716 |
Total accrued expenses and other current liabilities | $ 6,777 | $ 5,133 |
Stock-Based Compensation - Stoc
Stock-Based Compensation - Stock options (Details) - Employee Stock Option [Member] - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Number outstanding | |||||
Outstanding at the beginning of the period (in shares) | 2,188 | ||||
Granted (in shares) | 1,006 | ||||
Exercised (in shares) | (44) | ||||
Cancelled (in shares) | (355) | ||||
Outstanding at the end of the period (in shares) | 2,795 | 2,795 | 2,188 | ||
Exercisable at the end of the period (in shares) | 918 | 918 | |||
Vested and expected to vest at the end of the period (in shares) | 2,795 | 2,795 | |||
Weighted-average exercise price | |||||
Outstanding at the beginning of the period (in dollars per share) | $ 20.69 | ||||
Granted (in dollars per share) | 14.91 | ||||
Exercised (in dollars per share) | 6.74 | ||||
Cancelled (in dollars per share) | 17.11 | ||||
Outstanding at the end of the period (in dollars per share) | $ 19.28 | 19.28 | $ 20.69 | ||
Exercisable at the end of the period (in dollars per share) | 24.67 | 24.67 | |||
Vested and expected to vest at the end of the period (in dollars per share) | $ 19.28 | $ 19.28 | |||
Weighted-average remaining contractual life | |||||
Outstanding (in years) | 8 years 2 months 12 days | 8 years 1 month 6 days | |||
Exercisable at the end of the period (in years) | 6 years | ||||
Vested and expected to vest at the end of the period (in years) | 8 years 2 months 12 days | ||||
Aggregate intrinsic value | |||||
Outstanding | $ 18,118 | $ 18,118 | $ 4,273 | ||
Exercisable at the end of the period | 3,740 | 3,740 | |||
Vested and expected to vest at the end of the period | $ 18,118 | $ 18,118 | |||
Weighted-average fair value of options granted | $ 11.95 | $ 13.47 | $ 9.62 | $ 14.11 |
Stock-Based Compensation - Rest
Stock-Based Compensation - Restricted stock units (Details) - Restricted stock units - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 6 Months Ended | 12 Months Ended |
Jun. 30, 2023 | Dec. 31, 2022 | |
Number of restricted stock units | ||
Unvested restricted common stock at the beginning of the period (in shares) | 1,188 | |
Granted (in shares) | 737 | |
Vested (in shares) | (171) | |
Cancelled (in shares) | (223) | |
Unvested restricted common stock at the end of the period (in shares) | 1,531 | 1,188 |
Expected to convert | 1,531 | |
Weighted-average grant date fair value per share | ||
Unvested restricted common stock at the beginning of the period (in dollars per share) | $ 21.18 | |
Granted (in dollars per share) | 14.58 | |
Vested (in dollars per share) | 30.87 | |
Cancelled (in dollars per share) | 17.37 | |
Unvested restricted common stock at the end of the period (in dollars per share) | 17.47 | $ 21.18 |
Expected to convert (in dollars per share) | $ 17.47 | |
Unvested, Weighted-average remaining contractual life (in years) | 9 years 3 months 18 days | 9 years 7 months 6 days |
Expected to Convert, Weighted-average Remaining Contractual Life (in years) | 9 years 3 months 18 days | |
Unvested, Aggregate intrinsic value | $ 34,515 | $ 16,455 |
Expected to convert, Aggregate intrinsic value | $ 34,515 |
Stock-Based Compensation - St_2
Stock-Based Compensation - Stock-based compensation plans (Details) - 2017 ESPP - shares shares in Thousands | 6 Months Ended | ||
Jan. 03, 2023 | Jun. 30, 2023 | Dec. 31, 2021 | |
Stock-based compensation | |||
Employee stock purchase plan (in shares) | 70 | ||
Annual increase in the shares available for grant under the plan (as a percent of shares of common stock outstanding) | 1% | ||
Increase in the shares available for grant under the plan (in shares) | 372 |
Stock-Based Compensation - Shar
Stock-Based Compensation - Share-based compensation expense (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Stock-based compensation | ||||
Share-based compensation expense | $ 4,193 | $ 5,186 | $ 8,095 | $ 9,013 |
Cost of product revenue | ||||
Stock-based compensation | ||||
Share-based compensation expense | 200 | 137 | 387 | 225 |
Cost of service and other revenue | ||||
Stock-based compensation | ||||
Share-based compensation expense | 258 | 205 | 608 | 371 |
Research and development | ||||
Stock-based compensation | ||||
Share-based compensation expense | 405 | 482 | 775 | 880 |
Selling, general, and administrative | ||||
Stock-based compensation | ||||
Share-based compensation expense | 3,330 | $ 4,362 | 6,325 | $ 7,537 |
Restricted stock units and stock options | ||||
Stock-based compensation | ||||
Total unrecognized compensation cost related to unvested stock awards | $ 39,800 | $ 39,800 | ||
Period of recognition of unrecognized compensation cost | 2 years 10 months 24 days |
Stock-Based Compensation - Blac
Stock-Based Compensation - Black-Scholes valuation model Assumptions (Details) - $ / shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Employee Stock Option [Member] | ||||
Fair value assumptions: | ||||
Risk-free interest rate, Minimum | 3.50% | 2.70% | 3.50% | 1.40% |
Risk-free interest rate, Maximum | 4.20% | 3.20% | 4.20% | 3.20% |
Expected volatility, Minimum | 80.90% | 55.10% | 71.10% | 55% |
Expected volatility, Maximum | 82.10% | 56.20% | 82.10% | 56.20% |
Weighted-average grant date fair value | $ 11.95 | $ 13.47 | $ 9.62 | $ 14.11 |
Employee Stock Option [Member] | Minimum | ||||
Fair value assumptions: | ||||
Expected term (in years) | 5 years | 5 years 8 months 12 days | 5 years | 5 years 8 months 12 days |
Employee Stock Option [Member] | Maximum | ||||
Fair value assumptions: | ||||
Expected term (in years) | 5 years 1 month 6 days | 5 years 9 months 18 days | 5 years 1 month 6 days | 5 years 9 months 18 days |
Employee Stock Purchase Plan | ||||
Fair value assumptions: | ||||
Risk-free interest rate | 5.20% | 1.10% | 5.20% | |
Expected term (in years) | 6 months | 6 months | 6 months | 6 months |
Expected volatility | 72.80% | 55.70% | ||
Weighted-average grant date fair value | $ 2.25 | $ 4.62 | $ 2.24 | $ 4.76 |
Employee Stock Purchase Plan | Minimum | ||||
Fair value assumptions: | ||||
Risk-free interest rate | 0.70% | |||
Expected volatility | 72.80% | 51.90% | ||
Employee Stock Purchase Plan | Maximum | ||||
Fair value assumptions: | ||||
Risk-free interest rate | 1.10% | |||
Expected volatility | 82.50% | 55.70% |
Net Loss Per Share - Basic and
Net Loss Per Share - Basic and diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Net Loss Per Share | ||||
Net loss | $ (6,064) | $ (24,902) | $ (12,167) | $ (43,055) |
Basic weighted average common shares outstanding | 37,494 | 36,922 | 37,411 | 36,887 |
Diluted weighted average common shares outstanding | 37,494 | 36,922 | 37,411 | 36,887 |
Basic net (loss) income per share | $ (0.16) | $ (0.67) | $ (0.33) | $ (1.17) |
Diluted net (loss) income per share | $ (0.16) | $ (0.67) | $ (0.33) | $ (1.17) |
Net Loss Per Share - Common sha
Net Loss Per Share - Common share equivalents have been excluded from the calculation of diluted net loss per share (Details) - shares shares in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Net loss per share | ||||
Number of common share equivalents excluded in the calculation of diluted net loss per share | 4,498 | 3,506 | 4,367 | 3,142 |
Common stock and RSUs | ||||
Net loss per share | ||||
Number of common share equivalents excluded in the calculation of diluted net loss per share | 1,607 | 928 | 1,557 | 759 |
Employee Stock Option [Member] | ||||
Net loss per share | ||||
Number of common share equivalents excluded in the calculation of diluted net loss per share | 2,891 | 2,578 | 2,810 | 2,383 |
Income Taxes (Details)
Income Taxes (Details) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Income Taxes | ||||
Effective Income Tax Rate Reconciliation, Percent | 4% | 0% | 3.20% | 0% |
Goodwill (Details)
Goodwill (Details) - USD ($) $ in Millions | 3 Months Ended | ||
Sep. 30, 2022 | Jun. 30, 2023 | Dec. 31, 2022 | |
Changes in the carrying value of goodwill | |||
Goodwill impairment | $ 8.2 | ||
Goodwill | $ 0 | $ 0 |
Commitments and Contingencies -
Commitments and Contingencies - Purchase Commitments (Details) $ in Millions | 3 Months Ended | 12 Months Ended | 36 Months Ended | ||
Mar. 31, 2023 USD ($) | Dec. 31, 2023 item | Dec. 31, 2022 item | Dec. 31, 2024 item | Jun. 30, 2023 USD ($) | |
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Tenant improvements allowances | $ | $ 0.9 | ||||
Stratec Supply Agreement | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Number of discs shipped | item | 75,000 | ||||
Revenue from open purchase orders | $ | $ 3.7 | ||||
Purchase commitments expects to incur in next year | $ | $ 2.6 | ||||
Stratec Supply Agreement | Forecast | |||||
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] | |||||
Number of discs purchased | item | 515,000 | ||||
Number of discs shipped | item | 220,000 |
Commitments and Contingencies_2
Commitments and Contingencies - License agreements and Lease commitments (Details) - License agreements - USD ($) $ in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | ||
Aug. 31, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
License agreements | |||||
Royalty expense | $ 0 | $ 0 | $ 0 | $ 0 | |
Tufts | |||||
License agreements | |||||
Royalty expense | $ 0.4 | $ 0.4 | $ 0.8 | $ 0.7 | |
Harvard University | |||||
License agreements | |||||
Upfront Fee | $ 0.6 |
Commitments and Contingencies_3
Commitments and Contingencies - Future minimum commitments (Details) $ in Thousands | Jun. 30, 2023 USD ($) |
Commitments and Contingencies | |
2023 (remainder) | $ 3,487 |
2024 | 7,064 |
2025 | 7,228 |
2026 | 7,408 |
2027 | 7,641 |
2028 | 7,880 |
Thereafter | 15,741 |
Total lease payments | 56,449 |
Less: imputed interest | 13,085 |
Total operating lease liabilities | $ 43,364 |
Related Party Transactions (Det
Related Party Transactions (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Related party transactions | |||||
Cost of revenue | $ 11,891 | $ 14,789 | $ 23,421 | $ 29,782 | |
Accounts receivable (net of allowance for expected credit losses of $442 and $118 as of June 30, 2023 and December 31, 2022, respectively) | 24,423 | 24,423 | $ 19,017 | ||
Accounts payable | 3,238 | 3,238 | 3,836 | ||
Selling, General and Administrative Expense | 21,591 | 27,045 | 42,474 | 52,757 | |
Commitment to sponsor agreement | |||||
Product revenue | |||||
Related party transactions | |||||
Cost of revenue | 7,236 | 9,921 | 14,269 | 20,667 | |
Service revenue. | |||||
Related party transactions | |||||
Cost of revenue | 4,655 | $ 4,868 | 9,152 | $ 9,115 | |
Harvard University | |||||
Related party transactions | |||||
Related party revenue | 500 | 700 | |||
UltraDx | |||||
Related party transactions | |||||
Accounts receivable (net of allowance for expected credit losses of $442 and $118 as of June 30, 2023 and December 31, 2022, respectively) | 400 | 400 | 0 | ||
Accounts payable | $ 0 | $ 0 | $ 0 |
Restructuring (Details)
Restructuring (Details) $ in Millions | 3 Months Ended | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2023 USD ($) | Sep. 30, 2022 USD ($) position | Jun. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | |
Restructuring | ||||
Total headcount | position | 119 | |||
Goodwill impairment | $ 8.2 | |||
Impairment of long-lived assets | $ 0 | $ 0 | $ 25.6 | |
Property And Equipment [Member] | ||||
Restructuring | ||||
Impairment of long-lived assets | 16.3 | |||
Software and Software Development Costs [Member] | ||||
Restructuring | ||||
Impairment of long-lived assets | 1.1 | |||
Goodwill [Member] | ||||
Restructuring | ||||
Goodwill impairment | $ 8.2 |
Restructuring - Roll forward (D
Restructuring - Roll forward (Details) - Severance and Employee Benefit Costs $ in Thousands | 6 Months Ended |
Jun. 30, 2023 USD ($) | |
Restructuring | |
Balance at Beginning of period | $ 328 |
Accrual adjustments | (33) |
Cash payments | (16) |
Foreign currency translation | 5 |
Balance at End of period | $ 284 |
Variable Interest Entities (Det
Variable Interest Entities (Details) - USD ($) $ in Thousands, shares in Millions | 3 Months Ended | |
Jun. 30, 2023 | Dec. 31, 2022 | |
Other non-current assets | $ 2,282 | $ 1,298 |
UltraDx Limited Company | ||
Number of contingent consideration collaboration | 1 | |
Variable Interest Entity, Not Primary Beneficiary | ||
Other non-current assets | $ 1,300 | $ 300 |
Variable Interest Entity, Not Primary Beneficiary | UltraDx Limited Company | ||
Number of contingent consideration collaboration | 1 | |
Ownership interest | 5% |
Pay vs Performance Disclosure
Pay vs Performance Disclosure - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Pay vs Performance Disclosure | ||||
Net Income (Loss) | $ (6,064) | $ (24,902) | $ (12,167) | $ (43,055) |
Insider Trading Arrangements
Insider Trading Arrangements | 3 Months Ended |
Jun. 30, 2023 | |
Trading Arrangements, by Individual | |
Rule 10b5-1 Arrangement Adopted | false |
Non-Rule 10b5-1 Arrangement Adopted | false |
Rule 10b5-1 Arrangement Terminated | false |
Non-Rule 10b5-1 Arrangement Terminated | false |